Abstract: Abstract Objective: To evaluate the efficacy and safety of a regimen of low-dose interleukin-2 (IL-2) in the treatment for patients with locally advanced renal cell carcinoma (LA-RCC). Methods: We retrospectively analyses the records of all 38 patients who underwent radical nephrectomy which have been certified LA-RCC in our hospital from March 2003 to March 2006. Patients be sub grouped to three groups and group A, B and C received 18 MIU/M2, 1MIU/M2 and 0.5 MIU/M2 IL-2 subcutaneously QOD. Every three month all patients were examination by ultrasound, chest roentgenograms. Groups were compared using Student's t-test, and a probability (P) value of less than 0.05 was taken to indicate statistical significance. Results: 5，11 and 16 patients of group A,B and C complete the treatment at last. There was no significiantly difference among the three groups in the rate of tumor recurrence, tumor metastasis and death (P＞0.05). the side effect of IL-2 in group B and C was significiantly less than group A (P＜0.05). Conclusion: Adminstered low-dose IL-2 may be a safe and effective option to LA-RCC, especially for low-risk LA-RCC patients. Key words: Interleukin-2, Renal cell carcinoma, Immunotherapy

Key words: Interleukin-2, Renal cell carcinoma, Immunotherapy